Kyverna Therapeutics is trading at $6.64, down 5.01%, despite reporting positive one-year miv-cel data on September 24; its company-specific release contained no September 25 announcement or explanation for the decline.
- The September 24 clinical update supported continued Q4 2026 BLA filing plans.
- Elevated Treasury yields may be pressuring rate-sensitive biotechnology stocks, but broader indexes are modestly higher, so the connection is not conclusive.